DeepMed Research

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.otsuka-us.com

Clinical Trials

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Phase 1

Terminated

Conditions: Schizophrenia

Interventions: Drug: Brexpiprazole, OPDC-34712

First Posted Date: 2016-11-18

Last Posted Date: 2018-01-12

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 22

Registration Number: NCT02968121

Locations: 🇺🇸
CNRI, San Diego, California, United States
🇺🇸
Collaborative Neuro Science (CNS), Garden Grove, California, United States

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Phase 3

Completed

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions: Drug: Tolvaptan Matching-placebo
Drug: Tolvaptan

First Posted Date: 2016-11-16

Last Posted Date: 2023-01-03

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 91

Registration Number: NCT02964273

A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

Phase 1

Terminated

Conditions: Adult Attention-deficit Hyperactivity Disorder (ADHD)

Interventions: Drug: CTN XR1
Drug: CTN XR2
Drug: CTN XR3
Drug: CTN SR1

First Posted Date: 2016-07-11

Last Posted Date: 2022-02-18

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 16

Registration Number: NCT02827513

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

Phase 2

Completed

Conditions: Schizophrenia
Bipolar I Disorder
Major Depressive Disorder

Interventions: Drug: Aripiprazole + IEM (Ingestible Event Marker)

First Posted Date: 2016-03-30

Last Posted Date: 2018-05-23

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 49

Registration Number: NCT02722967

A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683

Phase 2

Completed

Conditions: Tuberculosis, Multidrug-Resistant

Interventions: Drug: Delamanid
Drug: OBR

First Posted Date: 2015-10-09

Last Posted Date: 2021-11-01

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 213

Registration Number: NCT02573350

Locations: 🇪🇪
Tartu University Lung Hospital, Tartu, Estonia
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Younsei University Medical Center, Seoul, Korea, Republic of

and more 5 locations

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Phase 2

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: CTN SR
Drug: Matching placebo

First Posted Date: 2015-09-11

Last Posted Date: 2021-11-11

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 85

Registration Number: NCT02547428

International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Phase 3

Completed

Conditions: Hyponatremia

Interventions: Drug: Tolvaptan

First Posted Date: 2015-05-20

Last Posted Date: 2016-01-21

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 111

Registration Number: NCT02449044

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Phase 3

Terminated

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type

Interventions: Drug: AVP-786

First Posted Date: 2015-05-18

Last Posted Date: 2025-01-20

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 1197

Registration Number: NCT02446132

Locations: 🇺🇸
Collier Neurologic Specialists, LLC, Naples, Florida, United States
🇺🇸
Naples Research, Inc, Naples, Florida, United States
🇺🇸
Bayside Clinical Research Site #556, New Port Richey, Florida, United States

and more 224 locations

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

Phase 3

Completed

Conditions: Agitation in Participants With Dementia of the Alzheimer's Type

Interventions: Drug: Placebo
Drug: AVP-786-18
Drug: AVP-786-28
Drug: AVP-786-42.63

First Posted Date: 2015-05-13

Last Posted Date: 2022-09-09

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 522

Registration Number: NCT02442778

Locations: 🇺🇸
Texas Neurology, P.A., Dallas, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Houston Methodist Neurological Institute, Houston, Texas, United States

and more 78 locations

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Phase 3

Completed

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type

Interventions: Drug: AVP-786
Drug: Placebo

First Posted Date: 2015-05-13

Last Posted Date: 2023-02-13

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 387

Registration Number: NCT02442765

Locations: 🇵🇷
Clinical Research Site, San Juan, Puerto Rico
🇪🇪
Clinical Research Site#2, Tallinn, Estonia
🇪🇪
Clinical Research Site#1, Tallinn, Estonia

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy